Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Published:2018-05 Issue:5 Volume:19 Page:603-615
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Ascierto Paolo A,Gogas Helen J,Arance Ana,Mandala Mario,Liszkay Gabriella,Garbe Claus,Schadendorf Dirk,Krajsova Ivana,Gutzmer Ralf,Chiarion-Sileni Vanna,Dutriaux Caroline,de Groot Jan Willem B,Yamazaki Naoya,Loquai Carmen,Moutouh-de Parseval Laure A,Pickard Michael D,Sandor Victor,Robert Caroline,Flaherty Keith T

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas;Krauthammer;Nat Genet,2015

2. BRAF mutation predicts sensitivity to MEK inhibition;Solit;Nature,2006

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity;Tsai;Proc Natl Acad Sci USA,2008

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

Cited by 729 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review;Case Reports in Oncology;2024-02-02

2. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

3. Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review;Cancers;2024-01-26

4. The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers;Cancers;2024-01-19

5. Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever;New England Journal of Medicine;2024-01-18